EP 2861242 B1 20180808 - GLUTEN-RELATED DISORDERS
Title (en)
GLUTEN-RELATED DISORDERS
Title (de)
GLUTENVERMITTELTE ERKRANKUNGEN
Title (fr)
TROUBLES ASSOCIÉS AU GLUTEN
Publication
Application
Priority
- US 201261661105 P 20120618
- US 201261725693 P 20121113
- US 2013046286 W 20130618
Abstract (en)
[origin: WO2013192163A1] The present invention features compositions and methods for treating gluten-related disorders. We describe compositions comprising one or more metabolites produced by Lactobacillus paracasei CBA L74, International Depository Accession Number LMG P-24778 that reduce cellular entry of gliadin peptides. The compositions may include a physiologically acceptable carrier, for example, a food product or a pharmaceutical carrier. The compositions can be administered to a subject having a gluten-related disorder, for example, celiac disease or gluten sensitivity.
IPC 8 full level
A23L 33/00 (2016.01); A23L 33/135 (2016.01); A61K 31/045 (2006.01); A61K 31/19 (2006.01); A61K 31/198 (2006.01); A61K 31/401 (2006.01); A61K 31/4172 (2006.01); A61K 31/708 (2006.01); A61K 35/747 (2015.01); A61K 38/10 (2006.01); A61K 38/16 (2006.01); A61K 45/06 (2006.01); A61P 37/00 (2006.01); C07K 14/335 (2006.01)
CPC (source: EP RU US)
A23L 33/135 (2016.07 - EP US); A23L 33/30 (2016.07 - EP US); A61K 31/045 (2013.01 - EP US); A61K 31/19 (2013.01 - EP US); A61K 31/198 (2013.01 - EP US); A61K 31/401 (2013.01 - EP US); A61K 31/4172 (2013.01 - EP US); A61K 31/708 (2013.01 - EP US); A61K 35/747 (2013.01 - EP RU US); A61K 38/164 (2013.01 - EP US); A61K 45/06 (2013.01 - US); A61P 1/00 (2017.12 - EP); A61P 19/00 (2017.12 - EP); A61P 25/00 (2017.12 - EP); A61P 29/00 (2017.12 - EP); A61P 29/02 (2017.12 - EP); A61P 37/00 (2017.12 - EP); C07K 14/335 (2013.01 - EP US); A23V 2002/00 (2013.01 - US)
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
DOCDB simple family (publication)
WO 2013192163 A1 20131227; AU 2013277316 A1 20150122; AU 2013277316 B2 20180301; AU 2018203543 A1 20180607; AU 2018203543 B2 20200227; BR 112014031666 A2 20171031; BR 112014031666 B1 20221004; CA 2876963 A1 20131227; CA 2876963 C 20210706; CN 104661671 A 20150527; CN 104661671 B 20201023; DK 2861242 T3 20181029; DK 3351554 T3 20210830; EP 2861242 A1 20150422; EP 2861242 A4 20160120; EP 2861242 B1 20180808; EP 3351554 A1 20180725; EP 3351554 B1 20210609; EP 3901164 A1 20211027; ES 2691087 T3 20181123; ES 2883552 T3 20211209; IN 10798DEN2014 A 20150904; MX 2014015314 A 20151029; MX 363899 B 20190405; NZ 702936 A 20170630; PL 2861242 T3 20190430; PL 3351554 T3 20211115; PT 2861242 T 20181107; PT 3351554 T 20210806; RU 2014150934 A 20160810; RU 2654705 C2 20180522; TR 201814973 T4 20181121; US 10245300 B2 20190402; US 2015174199 A1 20150625
DOCDB simple family (application)
US 2013046286 W 20130618; AU 2013277316 A 20130618; AU 2018203543 A 20180521; BR 112014031666 A 20130618; CA 2876963 A 20130618; CN 201380032073 A 20130618; DK 13807318 T 20130618; DK 18157990 T 20130618; EP 13807318 A 20130618; EP 18157990 A 20130618; EP 21165677 A 20130618; ES 13807318 T 20130618; ES 18157990 T 20130618; IN 10798DEN2014 A 20141217; MX 2014015314 A 20130618; NZ 70293613 A 20130618; PL 13807318 T 20130618; PL 18157990 T 20130618; PT 13807318 T 20130618; PT 18157990 T 20130618; RU 2014150934 A 20130618; TR 201814973 T 20130618; US 201314408108 A 20130618